AKT1 and malignant colon neoplasm: The involvement of increased regulation of AKT activity in drug resistance in BRAF mutant colon cancer was previously confirmed by higher basal levels of phospho-AKT in RKO cells intrinsically resistant to oxaliplatin in comparison with the responsive HCT116 colon cancer cells [4].